Latest stories on AGMB
Agomab Details Nov Era Phase 2b Trial Design For Ontunisertib In Fibrostenosing Crohns Disease
TipRanks53 · neutralproduct/pr
AgomAb Therapeutics: High Risk, High Reward Stock
Seeking Alpha61 · neutralgeneral
Agomab Shareholders Approve All 2025 Accounts And Board Reappointments At May 26 Agm
TipRanks50 · neutralgeneral